

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## P0891

Use of ureteric stent related mobile phone application UROSTENTZ App (free of cost) in COVID-19 for improving patient communication and safety: A prospective pilot study from a university hospital

Eur Urol;79(S 1):S1250

Zeeshan Hameed B.M., Somani B., Hegde P., Jayadeva S., Shah M., Naik N., Kankaria S., Hiremath V.

Kasturba Medical College , Dept. of Urology, Manipal, India

**Introduction & Objectives:** During COVID-19 led lockdown, a reliable system to monitor ureteral stent insertion and timely removal became an important facet of their use. This study looks at the use of 'Urostentz' smart- phone application (App) for stent procedures and whether it improved patient communication and safety during the lockdown.

**Materials & Methods:** The 'Urostentz' app was used for patients who underwent ureteric stent after ureteroscopy (URS) or percutaneous nephrolithotomy (PCNL) procedure. It is a smartphone app developed by the authors to improve patient safety, facilitate data collection, and provide an efficient interface to simplify ureteral stent tracking and patient communication. It also helps clinicians track stent related symptoms (SRS) and provide digital remote assistance. This App is available on Google Play store and an online version at <u>www.urostentz.com</u> for free of cost for the urologists and patients.

**Results:** A total of 33 patients registered with a mean age of 47.8 years (range: 18–80) and a male: Female ratio of 4.5:1. Of these, 29 (87.9%) used the Urostentz App, and 55.2% had SRS. The number of effective communication episodes ranged from 1–7/patient. Based on the symptoms and communication, stent was removed during lockdown (n=2), within 1 week of lockdown lifted (n=24) and within 2 weeks of lockdown lifted (n=5). None of the patients suffered any stent-related complications and there were no cases of forgotten stents or readmissions despite the lockdown and lack of communication using standard practices.

**Conclusions:** The Urostentz App proved to an effective medium of communication to provide guidance and personalized digital remote healthcare. It also allowed prompt removal of stents avoiding prolonged stent symptoms or forgotten stents. Such apps can have a much wider application in the post-COVID-era to reduce unnecessary post-procedural visits and reduce health care costs.